edoc

EULAR recommendations for the treatment of systemic sclerosis : a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

Kowal-Bielecka, O. and Landewé, R. and Avouac, J. and Chwiesko, S. and Miniati, I. and Czirjak, L. and Clements, P. and Denton, C. and Farge, D. and Fligelstone, K. and Földvari, I. and Furst, D. E. and Müller-Ladner, U. and Seibold, J. and Silver, R. M. and Takehara, K. and Toth, B. Garay and Tyndall, A. and Valentini, G. and van den Hoogen, F. and Wigley, F. and Zulian, F. and Matucci-Cerinic, Marco. (2009) EULAR recommendations for the treatment of systemic sclerosis : a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Annals of the rheumatic diseases : ARD, Vol. 68. pp. 620-628.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6003264

Downloads: Statistics Overview

Abstract

PURPOSE: The optimal treatment of systemic sclerosis (SSc) is a challenge because the pathogenesis of SSc is unclear and it is an uncommon and clinically heterogeneous disease affecting multiple organ systems. The aim of the European League Against Rheumatism (EULAR) Scleroderma Trials and Research group (EUSTAR) was to develop evidence-based, consensus-derived recommendations for the treatment of SSc. METHODS: To obtain and maintain a high level of intrinsic quality and comparability of this approach, EULAR standard operating procedures were followed. The task force comprised 18 SSc experts from Europe, the USA and Japan, two SSc patients and three fellows for literature research. The preliminary set of research questions concerning SSc treatment was provided by 74 EUSTAR centres. RESULTS: Based on discussion of the clinical research evidence from published literature, and combining this with current expert opinion and clinical experience, 14 recommendations for the treatment of SSc were formulated. The final set includes the following recommendations: three on SSc-related digital vasculopathy (Raynaud's phenomenon and ulcers); four on SSc-related pulmonary arterial hypertension; three on SSc-related gastrointestinal involvement; two on scleroderma renal crisis; one on SSc-related interstitial lung disease and one on skin involvement. Experts also formulated several questions for a future research agenda. CONCLUSIONS: Evidence-based, consensus-derived recommendations are useful for rheumatologists to help guide treatment for patients with SSc. These recommendations may also help to define directions for future clinical research in SSc.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Departement Biomedizin > Former Units at DBM > Rheumatologie FPS (Tyndall)
UniBasel Contributors:De Vere-Tyndall, Alan
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:British Medical Association
ISSN:0003-4967
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:01 Mar 2013 11:14
Deposited On:01 Mar 2013 11:13

Repository Staff Only: item control page